CAPR
Capricor Therapeutics, Inc.
5.41
+
0.26
5.05%
3 x 5.38
4 x 5.45
bid
ask
4 @ 04:00 PM
5.53+0.12 (2.22%)
Bearish
26
Bullish
88
sentiment
5.12
day range
5.49
2.71
52 week range
7.85
Prev Close5.15
Open5.14
Low5.12
High5.49
Volume638.69K
Avg. Volume316.54K
Market Cap170.43M
Inst. Own21.58%
Beta4.04
Short Ratio9.81
Div & Yield0.00 /
EPS-0.83
P/E0.00
1yr Target21.00
50day MA5.56
200day MA4.70
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2532.75
05:59 AM
-
46.85
1.82%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
163.45
05:59 AM
+
6.50
4.14%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -0.11 | N/A | N/A | N/A |
2024-02-29 | 2023-12 | -0.23 | -0.02 | 0.21 | 91.30% |
2023-11-14 | 2023-09 | -0.27 | -0.25 | 0.02 | 7.41% |
2023-08-07 | 2023-06 | -0.34 | -0.29 | 0.05 | 14.71% |
2023-05-11 | 2023-03 | -0.32 | -0.31 | 0.01 | 3.13% |
2023-03-15 | 2022-12 | 0 | -0.31 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-15 | HC Wainwright & Co. | Upgrade | Buy | |
2022-10-25 | Ladenburg Thalmann | Upgrade | Buy | |
2022-01-30 | HC Wainwright & Co. | Upgrade | Buy | |
2021-10-10 | HC Wainwright & Co. | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-10-05 | AUWAERTER PAUL GISBERT | Director | 5.00K | Purchase |
2023-04-16 | AVAT XAVIER | Former | 0.00 | Sale |
2023-10-22 | BERGMANN ANTHONY | Chief Financial Officer | 2.38K | Conversion of Exercise of derivative security |
2024-04-22 | COLLIER EARL M JR | Director | 56.86K | Conversion of Exercise of derivative security |
2023-02-13 | DUNBAR GEORGE W JR | Director | 10.56K | Conversion of Exercise of derivative security |
2022-11-02 | KRASNEY KAREN | General Counsel | 20.05K | Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.15M | 5.48M | 4.45% |
2023-06-29 | Blackrock Inc. | 410.92K | 1.96M | 1.59% |
2023-06-29 | Geode Capital Management, LLC | 298.32K | 1.43M | 1.16% |
2023-06-29 | Northern Trust Corporation | 105.51K | 504.32K | 0.41% |
2023-06-29 | Bank Of New York Mellon Corporation | 84.54K | 404.12K | 0.33% |
2023-06-29 | State Street Corporation | 84.92K | 405.94K | 0.33% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 767.24K | 3.67M | 2.98% |
2023-06-29 | Vanguard Extended Market Index Fund | 335.76K | 1.60M | 1.30% |
2023-05-30 | Fidelity Extended Market Index Fund | 114.14K | 517.07K | 0.44% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 50.16K | 325.05K | 0.19% |
2023-08-30 | iShares Micro Cap ETF | 49.37K | 319.93K | 0.19% |
2023-05-30 | Fidelity Total Market Index Fund | 43.59K | 197.45K | 0.17% |
Split
...
Split | Date |
---|---|
1 : 10 | 2019-06-05 |
0.02 : 1 | 2013-11-21 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
-
-
-
Sorry it was CANFOR mentioned, my error
-
$CAPR just mentioned on BNN
-
-
-
-
-
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
news.google.com • -
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
news.google.com • -
Capricor Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com • -
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript
seekingalpha.com • -
Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Capricor Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com • -
7 Undervalued Penny Stocks With Major Upside
investorplace.com • -
CAPR Stock: Why It Substantially Increased Today
pulse2.com • -
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
pennystocks.com • -
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
globenewswire.com • -
Capricor Therapeutics (CAPR) Investor Presentation - Slideshow
seekingalpha.com • -
Capricor Therapeutics (NASDAQ:CAPR) Coverage Initiated by Analysts at Maxim Group
thelincolnianonline.com • -
ThermoGenesis Holdings: Many Short-Term Catalysts In Low-Float Stock
seekingalpha.com • -
Capricor to Participate in BIO Digital International Convention
finance.yahoo.com • -
Here is What Hedge Funds Think About Capricor Therapeutics, Inc. (CAPR)
finance.yahoo.com • -
Moderna y Sorrento se disparan en Bolsa por sus avances en el desarrollo de una cura
cincodias.elpais.com • -
Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com • -
6 Stock Charts To Watch: AMRS, CYTK, DRNA, LX, MRNA, VAPO
investing.com • -
5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy
seekingalpha.com • -
Capricor (CAPR) Shares Could Hit $10, Says Analyst
finance.yahoo.com • -
Cómo hacerse millonario con una presunta cura en una sola sesión de Wall Street
cincodias.elpais.com • -
RDS.A, LYG among premarket losers
seekingalpha.com • -
108 Biggest Movers From Yesterday
benzinga.com • -
Capricor Therapeutics Shares Soar 250% On Successful COVID-19 Treatment News
finance.yahoo.com •